南微医学
(688029)
| 流通市值：179.39亿 | | | 总市值：179.39亿 |
| 流通股本：1.88亿 | | | 总股本：1.88亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,565,377,051.9 | 699,156,940.3 | 2,755,434,907.16 | 2,012,446,160.41 |
| 营业收入 | 1,565,377,051.9 | 699,156,940.3 | 2,755,434,907.16 | 2,012,446,160.41 |
| 二、营业总成本 | 1,114,540,760.78 | 501,585,822.52 | 2,064,317,241.62 | 1,467,685,015.45 |
| 营业成本 | 549,527,942.42 | 239,887,378.33 | 891,287,564.51 | 651,175,548.98 |
| 税金及附加 | 18,527,184.2 | 8,649,611.75 | 33,256,403.48 | 23,328,191.94 |
| 销售费用 | 337,540,256.86 | 149,159,764.01 | 646,301,355.07 | 465,159,798.73 |
| 管理费用 | 198,621,595.69 | 97,383,711.02 | 368,831,423.56 | 249,161,760.14 |
| 研发费用 | 88,282,277.32 | 38,058,328.95 | 174,369,113.18 | 111,568,259.5 |
| 财务费用 | -77,958,495.71 | -31,552,971.54 | -49,728,618.18 | -32,708,543.84 |
| 其中:利息费用 | 1,319,238.83 | 819,271.92 | 3,314,203.53 | 2,016,604.94 |
| 其中:利息收入 | 32,619,921.79 | 14,228,994.46 | 72,032,930.77 | 52,756,958.52 |
| 加:公允价值变动收益 | 403,050.42 | -7,595.89 | -472,933.8 | -6,431.02 |
| 加:投资收益 | 6,222,947.56 | 3,567,616.18 | 20,504,100.32 | 15,371,554.09 |
| 资产处置收益 | -7,425.13 | 32,402.17 | 722,720.64 | 7,295.87 |
| 资产减值损失(新) | -9,266,509.45 | -4,077,077.94 | -56,873,239.97 | -18,458,996.41 |
| 信用减值损失(新) | -1,177,033.94 | -1,424,241.01 | -5,541,279.32 | -5,049,438.24 |
| 其他收益 | 3,820,872.91 | 2,276,694.32 | 9,954,779.68 | 3,456,377.66 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 450,832,193.49 | 197,938,915.61 | 659,411,813.09 | 540,081,506.91 |
| 加:营业外收入 | 333,547.2 | 125,262.08 | 1,063,989.52 | 2,402,579.67 |
| 减:营业外支出 | 1,445,032.67 | 274,671.75 | 702,448.35 | 237,479.97 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 449,720,708.02 | 197,789,505.94 | 659,773,354.26 | 542,246,606.61 |
| 减:所得税费用 | 69,961,821.98 | 30,627,234.93 | 91,696,122.23 | 78,213,733.65 |
| 六、净利润 | 379,758,886.04 | 167,162,271.01 | 568,077,232.03 | 464,032,872.96 |
| 持续经营净利润 | 379,758,886.04 | 167,162,271.01 | 568,077,232.03 | 464,032,872.96 |
| 归属于母公司股东的净利润 | 363,379,408.08 | 160,936,939.7 | 553,226,633.36 | 451,093,598.62 |
| 少数股东损益 | 16,379,477.96 | 6,225,331.31 | 14,850,598.67 | 12,939,274.34 |
| (一)基本每股收益 | 1.94 | 0.86 | 2.95 | 2.41 |
| (二)稀释每股收益 | 1.94 | 0.86 | 2.95 | 2.41 |
| 八、其他综合收益 | 32,508,841.47 | 9,159,697.47 | 1,494,630.66 | -1,088,120.39 |
| 归属于母公司股东的其他综合收益 | 26,433,717.23 | 6,603,994.48 | 1,497,191.74 | -1,089,950.81 |
| 九、综合收益总额 | 412,267,727.51 | 176,321,968.48 | 569,571,862.69 | 462,944,752.57 |
| 归属于母公司股东的综合收益总额 | 389,813,125.31 | 167,540,934.18 | 554,723,825.1 | 450,003,647.81 |
| 归属于少数股东的综合收益总额 | 22,454,602.2 | 8,781,034.3 | 14,848,037.59 | 12,941,104.76 |
| 公告日期 | 2025-08-12 | 2025-04-29 | 2025-04-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |